T he primary goals of treatment in patients with non-infectious uveitis (NIU) are to control ocular inflammation and prevent sight-threatening complications such as macular edema and glaucoma. Systemic corticosteroids are the mainstay of treatment in NIU of the posterior segment (NIU-PS); however, long-term use is associated with treatment-limiting adverse effects. The need for agents with improved safety and tolerability coupled with recent insights into the pathogenesis of NIU-PS have led to the development of novel targeted interventions that potentially reduce or eliminate systemic corticosteroid exposure. Targeted interventions include intraocular drug delivery systems that provide high local concentrations at the site of inflammation with low systemic exposure and therapeutic agents, such as monoclonal antibodies that target specific pro-inflammatory cytokines and cytokine-mediated signaling pathways. The expanding range of therapeutic options enhances the ability to tailor therapy according to individual patient circumstances and optimize outcomes in patients with NIU-PS.
Uveitis comprises a range of intraocular inflammatory conditions of both infectious and non-infectious origin that can result in irreversible ocular damage and impaired vision or blindness. 1 Effective management is therefore vitally important to prevent ocular damage and preserve visual acuity and quality of life. [1] [2] [3] Therapeutic management of uveitis is dictated by etiology and anatomic location. 1 Infectious uveitis requires treatment of the underlying infectious pathogen, whereas treatment of non-infectious uveitis (NIU) is directed at controlling ocular inflammation. Anterior uveitis is typically managed with topical corticosteroids; however, treatment of posterior uveitis usually requires local and/or systemic therapy due to the limited penetration of topical agents into the posterior segment. 1, 2 Systemic corticosteroids are often prescribed as the initial treatment for NIU of the posterior segment (NIU-PS), but long-term use is associated with significant adverse effects that generally preclude prolonged administration. 2, 4 The treatment-limiting adverse effects of conventional therapies coupled with emerging insights into the pathogenesis of NIU have led to the development of novel, targeted therapeutic interventions for NIU-PS. Such interventions include agents aimed at a specific molecular pathway as well as therapies that utilize targeted delivery systems to achieve high therapeutic concentrations at the site of inflammation, and thereby minimize systemic exposure. Currently available therapies, including both targeted and non-specific agents, have been extensively reviewed elsewhere. 2, [4] [5] [6] [7] This article provides an overview of novel emerging targeted therapies that are currently under clinical investigation for the treatment of NIU-PS.
Systemic therapies
Evidence from experimental models of uveitis suggests that proinflammatory cytokines such as interleukin (IL)-6 and IL-23 promote the activation and clonal expansion of T helper (T H ) cells, particularly T H 17 cells, which weaken the blood-retinal barrier and allow leukocytes to enter and damage ocular tissues ( Figure 1 ). [8] [9] [10] Studies in patients with uveitis have shown elevated levels of IL-6, IL-10, IL-17, IL-22, IL-23, and tumor necrosis factor alpha (TNFa), supporting the hypothesis that T H 17-effector cytokines are central mediators of ocular inflammation and thus potential therapeutic targets. 11 These and other observations have led to the investigation of several systemic agents that target key mediators of inflammatory pathways for the treatment of NIU-PS ( Table 1) .
Sarilumab
Sarilumab (Kevzara ® ; Sanofi, Paris, France) is a human monoclonal antibody that binds to the IL-6 receptor and inhibits IL-6-mediated signaling. 12, 13 Sarilumab is currently approved for the 
Tocilizumab
Tocilizumab (Actemra ® ; Genentech, San Francisco, CA, US), a humanized monoclonal antibody against the IL-6 receptor, is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome. 16 The effect of tocilizumab in patients with NIU was evaluated in a phase I/II, open-label, randomized 17 A total of 37 patients received intravenous infusions of tocilizumab (4 or 8 mg/kg) every 4 weeks for 6 months. The primary outcome was the incidence and severity of systemic and ocular adverse events at month 6. Adverse events were generally consistent with observations from prior studies. 16 Two patients in the 8 mg/kg dose group experienced neutropenia after the first dose of tocilizumab, one of whom discontinued study treatment.
The most common ocular adverse event was increased IOP, which occurred in three eyes. One patient in each dose group received rescue therapy due to worsening inflammation. Analysis of efficacy outcomes at month 6 showed improvements in best corrected visual acuity . 21 Early analyses showed evidence of benefit in three patients with no significant adverse events reported during 28 weeks of follow up. The study is ongoing and is expected to be completed in December 2018.
Filgotinib
Filgotinib (Gilead Sciences, Inc., Foster City, CA, US) is an oral Janus kinase 1 (JAK1) inhibitor that is currently in phase III development for the treatment of rheumatoid arthritis and inflammatory bowel disease. 22, 23 IL-6, a proinflammatory cytokine involved in the pathogenesis of NIU-PS, 11 acts through a JAK1-mediated signaling pathway, 24 suggesting a potential 
Intraocular drug delivery
Targeted delivery of therapeutic agents via intraocular administration yields high therapeutic concentrations at the site of inflammation with potentially lower systemic exposure than oral or intravenous administration. Current routes of intraocular drug delivery include intravitreal injections and corticosteroid implants. Suprachoroidal injections, which utilize the naturally occurring suprachoroidal space between the sclera and choroid as a therapeutic reservoir, represent another potential option. 2, 28 The following section provides an overview of emerging local therapies for patients with NIU-PS ( Table 2) . 45 Corticosteroid implants years. 34 It is currently approved in the United States and Europe for the treatment of diabetic macular edema. 34, 35 Pooled data from two randomized, double-masked, sham-controlled studies in patients with diabetic macular edema showed that Iluvien was generally safe and well tolerated. 36 Cataract surgery was the most common drug-related serious adverse event, occurring in 41.1% and 7.0% of study eyes in the Iluvien and control groups, respectively. In accordance with a licensing and data sharing agreement with EyePoint Pharmaceuticals, an application seeking an expanded indication for the treatment of NIU-PS was filed in Europe in December 2017 based on the results of the two phase III trials evaluating the YUTIQ 0.18 mg fluocinolone implant.
37,38
Suprachoroidal injection 
39,40
Treatment was generally well tolerated, although IOP-related adverse events were more common in patients treated with suprachoroidal triamcinolone compared with sham controls (11.5% versus 0%, respectively).
Intravitreal sirolimus
Sirolimus is an immunomodulatory agent that inhibits the mammalian target of rapamycin (mTOR), a protein kinase involved in the regulation of T-cell activation, proliferation, and differentiation, and proinflammatory cytokine production. 41, 42 Oral sirolimus is currently approved for the prevention of organ rejection following renal transplant and the treatment of lymphangioleiomyomatosis. 
Intravitreal methotrexate
Methotrexate is a cytotoxic agent that exhibits dose-dependent inhibitory effects on neutrophils, macrophages, and T-cells. [52] [53] [54] [55] A pilot study evaluating intravitreal methotrexate (400 µg) in 15 patients with NIU showed statistically significant improvements in visual acuity, VH score, and macular thickness compared with baseline. corticosteroids were able to reduce the dose following treatment with intravitreal methotrexate. Treatment appeared to be generally well tolerated; however, adverse events were not prospectively assessed.
As noted above, a randomized trial comparing intravitreal methotrexate with either intravitreal ranibizumab or a corticosteroid implant in patients with uveitic macular edema is ongoing.
Intravitreal tesidolumab/LFG316
Tesidolumab/LFG316 (Novartis Pharmaceuticals; Basel, Switzerland)
is a monoclonal antibody against the complement 5 protein. were permitted to continue study treatment for an additional 6 months.
The study was completed in December 2017; however, published results
are not yet available. 
Conclusion
The primary goals of therapy in patients with chronic NIU-PS are to achieve durable control of ocular inflammation and prevent sight-threatening complications. 1, 2 Treatment-limiting systemic adverse effects associated with conventional therapies have prompted the development of therapies that allow targeted local delivery of drugs to the site of inflammation, while insights regarding the pathogenesis of NIU have led to the emergence of therapies that target specific mediators of autoinflammatory pathways.
The expanding range of targeted therapeutic options in development for the management of NIU is promising and will serve to enhance the ability to tailor therapy according to individual patient circumstances, while offering the potential for improved outcomes with reduced systemic exposure to corticosteroids. q
